XML 25 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Registered shares
Additional paid-in capital
Treasury shares
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive loss
Beginning of the period (in shares) at Mar. 31, 2020     173,106          
Beginning of the period (in shares) at Mar. 31, 2020         6,210      
Beginning of the period at Mar. 31, 2020 $ 1,489,268 $ (553) $ 30,148 $ 75,097 $ (185,896) $ 1,690,579 $ (553) $ (120,660)
Increase (Decrease) in Shareholders' Equity                
Total comprehensive income 959,002         947,257   11,745
Purchases of registered shares (in shares)         1,845      
Purchases of registered shares (164,952)       $ (164,952)      
Sale of shares upon exercise of stock options and purchase rights (in shares)         (1,786)      
Sale of shares upon exercise of stock options and purchase rights 43,810     3,130 $ 40,680      
Issuance of shares upon vesting of restricted stock units (in shares)         (1,080)      
Issuance of shares upon vesting of restricted stock units (32,082)     (53,093) $ 21,011      
Issuance of shares for contingent consideration (in shares)         (390)      
Issuance of shares from contingent consideration 28,463     18,847 $ 9,616      
Share-based compensation 85,538     85,538        
Cash dividends (146,705)         (146,705)    
End of the period (in shares) at Mar. 31, 2021     173,106          
End of the period (in shares) at Mar. 31, 2021         4,799      
End of the period balance at Mar. 31, 2021 2,261,789   $ 30,148 129,519 $ (279,541) 2,490,578   (108,915)
Increase (Decrease) in Shareholders' Equity                
Total comprehensive income 649,305         644,513   4,792
Purchases of registered shares (in shares)         4,607      
Purchases of registered shares (412,022)       $ (412,022)      
Sale of shares upon exercise of stock options and purchase rights (in shares)         (410)      
Sale of shares upon exercise of stock options and purchase rights 29,649     12,971 $ 16,678      
Issuance of shares upon vesting of restricted stock units (in shares)         (1,137)      
Issuance of shares upon vesting of restricted stock units (64,156)     (105,972) $ 41,816      
Issuance of shares for contingent consideration (in shares)         (4)      
Issuance of shares from contingent consideration 292     116 $ 176      
Share-based compensation 93,291     93,291        
Cash dividends $ (159,410)         (159,410)    
End of the period (in shares) at Mar. 31, 2022     173,106          
End of the period (in shares) at Mar. 31, 2022 7,855       7,855      
End of the period balance at Mar. 31, 2022 $ 2,398,738   $ 30,148 129,925 $ (632,893) 2,975,681   (104,123)
Increase (Decrease) in Shareholders' Equity                
Total comprehensive income 368,421         364,575   3,846
Purchases of registered shares (in shares)         7,562      
Purchases of registered shares (418,346)       $ (418,346)      
Sale of shares upon exercise of stock options and purchase rights (in shares)         (686)      
Sale of shares upon exercise of stock options and purchase rights 28,790     (5,636) $ 34,426      
Issuance of shares upon vesting of restricted stock units (in shares)         (968)      
Issuance of shares upon vesting of restricted stock units (29,163)     (68,710) $ 39,547      
Share-based compensation 71,801     71,801        
Cash dividends $ (162,681)         (162,681)    
End of the period (in shares) at Mar. 31, 2023     173,106          
End of the period (in shares) at Mar. 31, 2023 13,763       13,763      
End of the period balance at Mar. 31, 2023 $ 2,257,560   $ 30,148 $ 127,380 $ (977,266) $ 3,177,575   $ (100,277)